

Accelerating efficiency, data integrity and innovation for a global pharmaceutical manufacturer





Atos

About the client

With a portfolio that has advanced modern medicine, this top-20 global pharmaceutical company manufactures life-impacting drugs for millions of people. It prioritizes innovation and excellence by dedicating 25% of its revenue and more than 30,000 workers to research and development in search of new ways to improve human health.

As one of the most reputable pharmaceutical companies in the world, it controls the ongoing production of drugs that have a significant impact on millions of people's lives and propels research into new strategies for enhancing human health.

The value of combined improvements in operations, workflow, and user satisfaction allowed them to see a return on investment in five months after deployment, and they expect to see continued benefits at all levels.



Headquarters

United States



Industries

Pharmaceutical manufacturing, including human injectable manufacturing, filling, and packaging



Deployment

France, USA, China, and Japan

Challenge

- Accelerating efficiency in a GxPvalidated environment
- Utilizing a biometric solution with PPE
- Improving user experience across multiple environments

Solution

A wearable connected worker platform that blends biometrics, multi-factor, and continuous authentication with presence-aware capabilities for a password less and touchless MES signing application

Results

- Simultaneously increased efficiency, security, data integrity, and the user experience in one solution
- 93% employee adoption rate
- · ROI in 5 months

The challenge

In an industry where quality and compliance affect billions of lives, it can be difficult to digitalize or accelerate processes even when the benefits are significant. Drug and vaccine production are governed by some of the most comprehensive regulations and audits. At each step of the manufacturing process, employee signoff is required to ensure that rigorous quality and compliance standards have been achieved.

In accordance with regulations, the pharmaceutical company's operators applied signatures by either entering usernames and passwords into a manufacturing system, or with paper signatures. This meant that every operator had to enter dozens of signatures per day – a cumbersome practice that created a disruptive employee experience and added considerable time and expense to the manufacturing process.

The pharmaceutical company needed a solution that would address efficiency, data integrity and user experience, while simultaneously meeting the stringent demands of pharmaceutical manufacturing environments.

They wanted to enhance data integrity but reduce friction caused by using traditional credentials (such as passwords, pins, cards and fobs), and therefore began to evaluate biometric-enabled solutions. In order to deliver a superior employee experience, it was also necessary to eliminate the fragmentation brought on by signing in different environments and to guarantee compatibility with personal protective equipment (PPE). These were two crucial demands that traditional passwordless approaches could not satisfy. In addition, the customer wanted to remove the burden and cost of password resets and terminal locks.

All of this needed to be accomplished across multiple sites in multiple countries, multiple production lines, and varied environments including clean rooms and non-clean rooms.

The solution

The pharmaceutical decided on the combined solution from Nymi and Evidian because it was the only one that could meet all of the essential criteria.

With its workplace wearable, the Nymi BandTM, is activated through a user's fingerprint and ECG. It remains active through On-Body Detection, and in conjunction with being presence-aware, it delivers a seamless connection of workplace activities to employees (even through PPE). This innovative combination of biometrics provides the highest level of identity assurance to strengthen data integrity, while continuous authentication removes user friction and enhances security.

Finally, the solution leverages standards- based and partner integrations to unify the employee experience across multiple environments and sites with no need for organizations to upgrade their legacy applications and systems. These integrations ensured the new platform's easy deployment and compatibility with the pharmaceutical manufacturer's Evidian solution.

The results

Combining Nymi with Evidian SSO and Authentication Manager increased manufacturing efficiency, productivity, systems security, data integrity and compliance throughout its global facilities.

The replacement of multiple disruptive log-ins with a single streamlined solution on a platform improved worker productivity and satisfaction, while also enhancing security. Additionally, deploying this new type of wearable platform allowed the enterprise to replace manual e- signatures with a fluid and touchless intent- based action of the wrist.

The incredible ease-of-use of the combined Nymi and Atos Evidian solution has contributed to a 93% user adoption rate. The combined value of improvements in operations, workflow and user satisfaction allowed to see a return on investment in five months after deployment, and they expect to see continued benefits at all levels.



Nymi & Evidian

The joint solution from Nymi and Atos Evidian provided compounded benefits by integrating passwordless and single sign-on (SSO) capabilities. The Nymi Band connects to Evidian's Enterprise SSO and Authentication Manager to replace passwords with a biometric-enabled wearable. This approach also protects the enterprise from unwanted lateral movement within networks when employees connect to the workplace. The Evidian solution enabled the company to use state-of-the-art authentication without needing to upgrade applications that otherwise would have had to go through an expensive revalidation process. Nymi was then able to build on Evidian's value through its easy platform integration.

This partnership strengthens security by connecting strict password policy enforcement with continuous multi-factor authentication that secures access to workstations, data and applications. Together, Nymi and Evidian provide a non-intrusive, easy-to-deploy solution that makes work easier and more secure for the company and its employees.

About Atos

Atos is a global leader in digital transformation with 111,000 employees and annual revenue of c. \in 11 billion. European number one in cybersecurity, cloud and high performance computing, the Group provides tailored end-to-end solutions for all industries in 71 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea), listed on Euronext Paris and included in the CAC 40 ESG and Next 20 Paris Stock indexes.

The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Find out more about us atos.net atos.net/career

Let's start a discussion together









About Nymi

Nymi has created an enterprise service that connects people to their entire workplace through one platform and wearable. Connecting workersas-a- service is the safe, secure, and simple way for organizations to unlock agility, security, and scalability for the digital future.

Our customers represent 9 of the top 10 pharmaceutical manufacturers globally and we continue to expand into critical infrastructure sectors.

Atos is a registered trademark of Atos SE. © Copyright Atos SE. Confidential Information owned by Atos group, to be used by the recipient only.

This document, or any part of it, may not be reproduced, copied, circulated and/or distributed nor quoted without prior written approval of Atos.